- Johnson & Johnson (JNJ) traded lower in the premarket on Friday after the New Jersey-based pharmaceutical giant announced a setback in a mid-stage trial for JNJ-95475939 (JNJ-5939), its experimental therapy for a skin condition called atopic dermatitis (eczema).
- Citing a
J&J eczema therapy trails expectations in mid-stage trial
